MC2-25-C1 new drug for uremic pruritus starts phase II clinical trial
ADC评论
September 16, 2022
On September 14, MC2 Therapeutics announced that it had completed the first patient dosing of the Phase II MC2-25-C1 trial. The trial was designed to
